CureVac - Ingmar Hoerr, CEO
Added on 29 Mar 2017
Watched
3,315
times
CureVac, a clinical stage biopharmaceutical company from Tübingen, Germany, is pioneering the field of mRNA-based technology platforms for medical purposes with which mRNA is specifically optimised and formulated. Since 2000 the company develops novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases – both under the brand RNActive®. CureVac has successfully established the first GMP (good manufacturing practice) facility worldwide for the manufacture of RNA and mRNA and has pioneered mRNA-based drugs in clinical studies.
BÌNH LUẬN
Tài khoản của bạn không có hình đại diện
Để tiếp tục đăng bình luận, vui lòng chọn hình đại diện tạm thời
Confirm
Một số phần bị sai, vui lòng thử lại
Or
Tải lên tài khoản Y8
Hủy